Analysts See $-0.11 EPS for Galectin Therapeutics, Inc. (GALT)

March 15, 2018 - By Maria Brooks

 Analysts See $ 0.11 EPS for Galectin Therapeutics, Inc. (GALT)
Investors sentiment decreased to 0.67 in Q3 2017. Its down 1.22, from 1.89 in 2017Q2. It dropped, as 7 investors sold Galectin Therapeutics, Inc. shares while 8 reduced holdings. 4 funds opened positions while 6 raised stakes. 3.22 million shares or 4.39% less from 3.37 million shares in 2017Q2 were reported.
Riggs Asset Managment holds 1,000 shares. Susquehanna International Group Limited Liability Partnership holds 0% of its portfolio in Galectin Therapeutics, Inc. (NASDAQ:GALT) for 168,648 shares. Tiedemann Wealth Mngmt Lc holds 15,000 shares. Next Financial Group Inc Inc has 0% invested in Galectin Therapeutics, Inc. (NASDAQ:GALT) for 1,000 shares. Da Davidson accumulated 690,960 shares. Comml Bank Of America De reported 7,603 shares stake. Neuberger Berman Group Ltd Liability has invested 0% in Galectin Therapeutics, Inc. (NASDAQ:GALT). State Street holds 11,450 shares. Benchmark Capital Advsrs invested in 0.32% or 194,200 shares. Northern Corporation accumulated 80,739 shares. Thrivent Financial For Lutherans owns 6,000 shares. Illinois-based Grp One Trading Ltd Partnership has invested 0% in Galectin Therapeutics, Inc. (NASDAQ:GALT). Morgan Stanley invested in 103,436 shares or 0% of the stock. Cetera Advisor Netwr Limited Liability Corporation reported 15,721 shares. Blackrock holds 200,378 shares or 0% of its portfolio.

Since January 25, 2018, it had 2 insider purchases, and 2 sales for $2.64 million activity. 244,444 shares were sold by CZIRR JAMES C, worth $1.33M on Thursday, January 25. FREEMAN KEVIN D had bought 2,000 shares worth $8,191.

Analysts expect Galectin Therapeutics, Inc. (NASDAQ:GALT) to report $-0.11 EPS on March, 29 before the open.They anticipate $0.02 EPS change or 15.38 % from last quarter’s $-0.13 EPS. After having $-0.13 EPS previously, Galectin Therapeutics, Inc.’s analysts see -15.38 % EPS growth. The stock decreased 8.29% or $0.43 during the last trading session, reaching $4.76. About 376,023 shares traded. Galectin Therapeutics, Inc. (NASDAQ:GALT) has risen 62.09% since March 15, 2017 and is uptrending. It has outperformed by 45.39% the S&P500.

Galectin Therapeutics, Inc. (NASDAQ:GALT) Ratings Coverage

Among 5 analysts covering Galectin Therapeutics (NASDAQ:GALT), 3 have Buy rating, 1 Sell and 1 Hold. Therefore 60% are positive. Galectin Therapeutics had 12 analyst reports since September 21, 2015 according to SRatingsIntel. The company was downgraded on Monday, October 3 by FBR Capital. The stock of Galectin Therapeutics, Inc. (NASDAQ:GALT) earned “Buy” rating by H.C. Wainwright on Monday, March 28. The rating was downgraded by H.C. Wainwright to “Neutral” on Thursday, September 29. The rating was maintained by Roth Capital with “Buy” on Thursday, December 7. As per Wednesday, September 28, the company rating was downgraded by TH Capital. Roth Capital downgraded the shares of GALT in report on Wednesday, September 28 to “Sell” rating. As per Thursday, March 30, the company rating was upgraded by H.C. Wainwright. Roth Capital maintained Galectin Therapeutics, Inc. (NASDAQ:GALT) rating on Thursday, January 4. Roth Capital has “Buy” rating and $8.0 target. The firm has “Buy” rating given on Monday, September 21 by H.C. Wainwright. As per Wednesday, June 14, the company rating was maintained by H.C. Wainwright.

Galectin Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic disease and cancer. The company has market cap of $172.02 million. The company's lead product candidate includes galectin-3 inhibitor , a galactoarabino-rhamnogalacturonan polysaccharide polymer for the treatment of liver fibrosis and liver cirrhosis in non-alcoholic steatohepatitis patients, as well as for the treatment of cancer. It currently has negative earnings. It also engages in developing GM-CT-01, which is in pre-clinical development state for the treatment of cardiac and vascular fibrosis, as well as focuses on developing GR-MD-02 for the treatment of psoriasis.

More notable recent Galectin Therapeutics, Inc. (NASDAQ:GALT) news were published by: which released: “Galectin Therapeutics to Present at BIO CEO & Investor Conference” on February 06, 2018, also with their article: “Galectin Therapeutics Provides Corporate Update at Annual Meeting” published on December 14, 2017, published: “Galectin Therapeutics Granted Patents in China and Japan that Support NASH and …” on January 25, 2018. More interesting news about Galectin Therapeutics, Inc. (NASDAQ:GALT) were released by: and their article: “Galectin Therapeutics to Present at Two International Conferences in March” published on March 09, 2018 as well as‘s news article titled: “Galectin Therapeutics Reports 2017 Third Quarter Financial Results and …” with publication date: November 07, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.